Table 1.
Clinical characteristics, treatments in patients at the time of diagnosis of AH-MCL (includes blastoid and pleomorphic histology): overall, AH-DN, and AH-t
| Characteristic | Overall (N = 183) | AH-DN (n = 108) | AH-t (n = 75) | P |
|---|---|---|---|---|
| Age, median (range), y | 65 (31-95) | 63 (31-83) | 67 (39-95) | .009 |
| Sex, male/female, n (%) | 137 (75)/46 (25) | 80 (74)/28 (26) | 57 (76)/18 (24) | .76 |
| Histology type, n (%) | .187 | |||
| Blastoid/pleomorphic | 152 (83)/31 (17) | 93 (86)/15 (14) | 59 (79)/16 (21) | |
| PS-ECOG, n (%) | <.001 | |||
| 0 | 40 (22) | 12 (11) | 28 (38) | |
| 1 | 103 (57) | 76 (71) | 27 (36) | |
| 2 | 27 (15) | 17 (16) | 10 (13) | |
| 3 | 5 (3) | 2 (2) | 3 (4) | |
| 4 | 6 (3) | 0 (0) | 6 (8) | |
| B symptoms, yes/no, n (%) | 35 (19)/147 (81) | 23 (21)/84 (78) | 12 (16)/63 (84) | .35 |
| Leukemic phase, yes/no, n (%) | 49 (27)/132 (73) | 44 (41)/64 (59) | 5 (7)/68 (93) | <.001 |
| Bone marrow involved by MCL, yes/no, n (%) | 106 (67)/53 (33) | 85 (79)/23 (21) | 21 (41)/30 (59) | <.001 |
| CNS involvement, yes/no, n (%) | 8 (5)/175 (95) | 4 (4)/104 (96) | 4 (5)/71 (95) | .71 |
| Light chain type, κ/λ, n (%) | 90 (60)/59 (40) | 59 (63)/34 (37) | 31 (55)/25 (45) | .32 |
| Ki-67, median (range), % | 70 (10-100) | 67 (10-100) | 70 (10-100) | .154 |
| LDH above the ULN, yes/no, median (range), IU/L | 79 (45)/96 (55) | 52 (49)/53 (51) | 27 (38)/43 (61) | .15 |
| SOX-11 expression (±), n (%) | 30 (81)/7 (19) | 11 (85)/2 (15) | 19 (80)/5 (20) | .99 |
| WBC, median (range), 103/µL | 6.2 (1-205) | 7 (1-205) | 5 (2-85) | .002 |
| Serum LDH, median (range), IU/L | 574 (202-42 000) | 609 (202-42 000) | 550 (214-30 000) | .60 |
| Serum β2-microglobulin, median (range), mg/dL | 3 (1-19) | 3 (2-19) | 3 (1-8) | .907 |
| Hemoglobin, median (range), g/dL | 12 (7-16) | 12 (7-16) | 13 (7-15) | .46 |
| Platelet count, median (range), 103/µL | 163 (8-615) | 189 (8-615) | 152 (17-427) | .05 |
| Absolute monocyte count, median (range), 103/µL | 0.5 (0.07-25) | 0.5 (0.07-25) | 0.5 (0.1-3) | .99 |
| Absolute lymphocyte count, median (range), 103/µL | 1.1 (0.1-78) | 1 (0.1-78) | 1 (0.1-11) | .03 |
| First-line treatments, n (%) | <.001 | |||
| R-HCVAD based | 59 (36) | 51 (50) | 8 (13) | |
| R-HCVAD based and SCT consolidation | 14 (8) | 13 (13) | 1 (2) | |
| R-chemotherapy | 37 (23) | 28 (28) | 9 (15) | |
| R-chemotherapy and SCT consolidation | 7 (4) | 6 (6) | 1 (2) | |
| R-lenalidomide with/without other agents | 8 (5) | 1 (1) | 7 (12) | |
| R-lenalidomide with/without other agents and SCT | 1 (1) | 0 (0) | 1 (2) | |
| Ibrutinib/other BTK inhibitor | 16 (10) | 0 (0) | 16 (26) | |
| Ibrutinib/other BTK inhibitor and SCT consolidation | 3 (2) | 0 (0) | 3 (5) | |
| Miscellaneous | 18 (12) | 3 (3) | 15 (25) | |
| Response to first-line treatment, CR/no CR, n (%) | 90 (56)/72 (44) | 75 (74)/27 (26) | 15 (25)/45 (75) | <.001 |
PS-ECOG, performance status, Eastern Cooperative Oncology Group; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-HCVAD, rituximab with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytosine arabinoside; ULN, upper limit of normal; WBC, white blood cell count.